Onyx Pharmaceuticals Inc, which is seeking a buyer after rejecting a takeover bid by Amgen Inc as too low, on Thursday reported a narrower second-quarter loss on revenue from its new blood cancer drug Kyprolis.The biotechnology company said it had a net loss of $53.2 million, or 73 cents per share, half the loss of $106 million, or $1.65 per share, a year ago.Excluding one-time items, Onyx lost 40 cents per share. Analysts on average had expected a loss of 42 cents per share, according to Thomson Reuters I/B/E/S.Revenue for the quarter more than doubled to $153 million, edging past Wall Street estimates of $151.7 million.
Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Shares of AMGN fell by 1.8% or $-2.02/share to $110.38. In the past year, the shares have traded as low as $80.60 and as high as $114.95. On average, 3379480 shares of AMGN exchange hands on a given day and today's volume is recorded at 4754396.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. Shares of ONXX fell by 0.62% or $-0.79/share to $127.42. In the past year, the shares have traded as low as $66.37 and as high as $136.87. On average, 1872070 shares of ONXX exchange hands on a given day and today's volume is recorded at 2925104.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 1.26% or $0.43/share to $34.50. In the past year, the shares have traded as low as $26.71 and as high as $36.04. On average, 992622 shares of TRI exchange hands on a given day and today's volume is recorded at 688713.
Thomson Reuters Corporation (Thomson Reuters) is a provider of information for the world?s businesses and professionals. Shares of TRI traded higher by 0.28% or $0.1/share to $35.60. In the past year, the shares have traded as low as $26.65 and as high as $36.98. On average, 1010770 shares of TRI.TO exchange hands on a given day and today's volume is recorded at 550931.
Source
